• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Surmodics Inc. (Amendment)

    2/2/24 9:53:02 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email
    SC 13G/A 1 ea192418-13ga2soleus_surmo.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

     

    Surmodics, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    868873100

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. 868873100

     

    1  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Master Fund, L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐ 

    3  

    SEC USE ONLY

     

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

      5  

    SOLE VOTING POWER

     

    0

      6  

    SHARED VOTING POWER

     

    771,700(1)

      7  

    SOLE DISPOSITIVE POWER

     

    0

      8  

    SHARED DISPOSITIVE POWER

     

    771,700(1)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    771,700(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    FI

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC (“Soleus Capital”) is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC (“SCG”) is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 14,156,000 shares of common stock outstanding of the Issuer as of November 17, 2023, as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 22, 2023 (the “Form 10-K”).

     

    2

     

     

    CUSIP NO. 868873100

     

    1  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐ 

    3  

    SEC USE ONLY

     

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

      5  

    SOLE VOTING POWER

     

    0

      6  

    SHARED VOTING POWER

     

    771,700(1)

      7  

    SOLE DISPOSITIVE POWER

     

    0

      8  

    SHARED DISPOSITIVE POWER

     

    771,700(1)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    771,700(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 14,156,000 shares of common stock outstanding of the Issuer as of November 17, 2023 as reported in the Form 10-K.

     

    3

     

     

    CUSIP NO. 868873100

     

    1  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Group, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐ 

    3  

    SEC USE ONLY

     

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

      5  

    SOLE VOTING POWER

     

    0

      6  

    SHARED VOTING POWER

     

    771,700(1)

      7  

    SOLE DISPOSITIVE POWER

     

    0

      8  

    SHARED DISPOSITIVE POWER

     

    771,700(1)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    771,700(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 14,156,000 shares of common stock outstanding of the Issuer as of November 17, 2023, as reported in the Form 10-K.

     

    4

     

     

    CUSIP NO. 868873100

     

    1  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Guy Levy

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐ 

    3  

    SEC USE ONLY

     

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

      5  

    SOLE VOTING POWER

     

    0

      6  

    SHARED VOTING POWER

     

    771,700(1)

      7  

    SOLE DISPOSITIVE POWER

     

    0

      8  

    SHARED DISPOSITIVE POWER

     

    771,700(1)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    771,700(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    FOOTNOTES

     

    (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2) This percentage is calculated based upon 14,156,000 shares of common stock outstanding of the Issuer as of November 17, 2023, as reported in the Form 10-K.

     

    5

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Surmodics, Inc.

      

    (b)Address of Issuer’s Principal Executive Offices

     

    9924 West 74th Street

    Eden Prairie, MN 55344

     

    Item 2.

     

    (a)Name of Person(s) Filing

     

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

    (b)Address of Principal Business Office or, if none, Residence

     

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    (c)Citizenship

     

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC—Delaware

    Guy Levy – United States

     

    (d)Title of Class of Securities

     

    Common Stock

     

    6

     

     

    (e)CUSIP Number

     

    868873100

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.)
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
         
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

     

    Soleus Capital Master Fund, L.P. (“Master Fund”) holds, as of the close of business on December 31, 2023, an aggregate of 771,700 shares of the common stock of the Issuer. As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

     

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital, LLC or Soleus Capital Group, LLC is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    7

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 2, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By:

    /s/ Guy Levy

      Name:  Guy Levy
      Title: Managing Member
       
    Date: February 2, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By:

    /s/ Guy Levy

      Name: Guy Levy
      Title: Managing Member
       
    Date: February 2, 2024 Soleus Capital Group, LLC
         
      By:

    /s/ Guy Levy

      Name: Guy Levy
      Title: Managing Member
       
    Date: February 2, 2024

    /s/ Guy Levy

      Name: Guy Levy

     

    Footnotes:

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

     

    9 

     

    Get the next $SRDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    Leadership Updates

    Live Leadership Updates

    See more
    • KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

      6/27/23 7:05:00 AM ET
      $KRMD
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Financials

    Live finance-specific insights

    See more
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

      1/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

      4/30/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

      Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the second quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics als

      4/28/25 6:00:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

      European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March 2025 edition of the Eur

      4/22/25 7:00:00 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    SEC Filings

    See more
    • SEC Form SD filed by Surmodics Inc.

      SD - SURMODICS INC (0000924717) (Filer)

      5/20/25 5:30:03 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surmodics Inc.

      SCHEDULE 13G/A - SURMODICS INC (0000924717) (Subject)

      5/13/25 4:44:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Surmodics Inc.

      10-Q - SURMODICS INC (0000924717) (Filer)

      4/30/25 7:55:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/14/24 3:36:00 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      11/6/24 1:30:21 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

      SC 13G/A - SURMODICS INC (0000924717) (Subject)

      10/23/24 10:43:41 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Heine Lisa Wipperman covered exercise/tax liability with 2,115 shares and exercised 2,640 shares at a strike of $27.30, increasing direct ownership by 4% to 13,978 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/20/25 4:12:56 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Dantzker David exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,216 shares, increasing direct ownership by 3% to 40,183 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:22:54 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Director Bedoya Jose H exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,224 shares, increasing direct ownership by 4% to 30,008 units (SEC Form 4)

      4 - SURMODICS INC (0000924717) (Issuer)

      2/18/25 5:20:51 PM ET
      $SRDX
      Medical/Dental Instruments
      Health Care

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Surmodics upgraded by Lake Street with a new price target

      Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

      3/7/25 8:21:43 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics upgraded by Needham with a new price target

      Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

      6/13/23 7:48:05 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care
    • Surmodics downgraded by Needham

      Needham downgraded Surmodics from Buy to Hold

      2/13/23 7:24:21 AM ET
      $SRDX
      Medical/Dental Instruments
      Health Care